Posted byOrthoEx Posted in
Posted on Oct 03, 2018

October 03, 2018 / By RTT News

( – Shares of SeaSpine Holdings Corp. ( SPNE ) have returned more than 60% year-to-date, clearly outpacing the 12% gain of the iShares Nasdaq Biotechnology index.

SeaSpine is a medical technology company focused on developing and commercializing surgical solutions namely, orthobiologics and spinal implants, for the treatment of patients suffering from spinal disorders.

Between 2012 and 2017, Company launched a total of 30 products, thanks to increased annual research and development spending. This year, more than 6 products are expected to be launched, of which 4 products have already been launched.

SeaSpine reports revenue in two product categories namely orthobiologics and spinal implants.

The orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. The spinal implant portfolio consists of an extensive line of products to facilitate spinal fusion in MIS, complex spine, deformity and degenerative procedures.

The Company generates 90% of its revenue from the U.S. spine market. Apart from the U.S., the Company’s products are sold in over 30 countries worldwide.